Epstein-Barr Viral Load Assessment in Immunocompetent Patients With Fulminant Infectious Mononucleosis
Authors:
- Jan A. M. van LaarJLJan A. M. van Laar
- Corinne M. P. BuysseCBCorinne M. P. Buysse
- Ann C. T. M. VossenAVAnn C. T. M. Vossen
- Björn HjálmarssonBHBjörn Hjálmarsson
- Bart van Den BergBBBart van Den Berg
- Kirsten van LomKLKirsten van Lom
- Jaap DeinumJDJaap Deinum
- 8 April 2002
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (7) , 837-839
Abstract
We describe 2 immunocompetent adolescents with fulminant infectious mononucleosis and virus-associated hemophagocytosis. A new quantitative polymerase chain reaction revealed high serum Epstein-Barr virus DNA levels in these patients. One patient died with an increasing viral load not responding to corticosteroids followed by antiviral and intensified immunomodulatory treatment. The other patient received corticosteroids and acyclovir at diagnosis; her rapid recovery was heralded by a steep decline of viral load. We propose monitoring the clinical course of fulminant infectious mononucleosis in immunocompetent patients by Epstein-Barr virus DNA quantification and prompt corticosteroid and antiviral therapy when viral load is high.Keywords
This publication has 2 references indexed in Scilit:
- Requirement for Etoposide in the Treatment of Epstein-Barr Virus–Associated Hemophagocytic LymphohistiocytosisJournal of Clinical Oncology, 2001
- Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cellsBlood, 2000